Beam Therapeutics Inc., a biotechnology company based in Cambridge, Massachusetts, is at the forefront of developing innovative DNA base editing technologies aimed at treating human diseases. As of August 6, 2026, the company’s stock is trading on the Nasdaq with a close price of $27.48. This represents a significant fluctuation over the past year, with a 52-week high of $38.26 recorded on July 6, 2026, and a 52-week low of $15.60 on August 20, 2025. The company’s market capitalization stands at approximately $2.84 billion.
Beam Therapeutics operates within the Health Care sector, focusing on cutting-edge genetic editing technologies. These technologies are designed to precisely modify DNA sequences, offering potential treatments for a variety of genetic disorders. The company’s efforts are concentrated in the State of Massachusetts, where it serves its customer base.
Despite its innovative approach and potential in the biotechnology field, Beam Therapeutics currently reports a Price Earnings (P/E) ratio of -32.77. This negative P/E ratio indicates that the company is not yet profitable, which is not uncommon for companies in the early stages of developing groundbreaking technologies.
For those interested in learning more about Beam Therapeutics’ activities and offerings, further information is available on their website at www.beamtx.com . The company continues to focus on advancing its DNA base editing technologies, with the aim of bringing transformative treatments to patients suffering from genetic diseases.
